

Abstract citation ID: bvac150.193

## **Adrenal**

**PSAT017**

### ***A Case of Aldosterone- and Cortisol Co-secreting Adrenal Cortical Neoplasm with Lipomatous and Myelolipomatous Metaplasia***

*Sruthi Jinna, M.D, John Jun, MD, MS, Firas Petros, MD, Lauren Stanoszek, MD, PhD, and Rokana Taftaf, MD, PhD*

**Background:** Adrenal lipomatous tumors are uncommon fatty tumors of the adrenal glands with myelolipoma being the most common histologic feature. Adrenal myelolipoma is a benign adrenal cortical neoplasm composed of fat and myeloid tissue, commonly diagnosed if fat composition of tumor is more than 50% on cross-sectional imaging studies. The myelolipomatous metaplasia is a secondary degenerative change in primary adrenal tumor, usually seen in benign adrenocortical adenomas and rarely in adrenocortical carcinomas and cortical neoplasms of uncertain malignant potential. Adrenocortical neoplasms are classified as benign or malignant based on modified Weiss score, when the criteria are not clear, the tumor is classified as a neoplasm of uncertain malignant lesion. As adrenal lipomatous tumors are usually benign and non-functional, patients with these tumors often do not undergo hormonal evaluation.

**Clinical Case:** A 58-year-old female with a history of hypertension diagnosed at age 35 years, on five antihypertensive agents and a history of intermittent spontaneous hypokalemia, was found to have a 6 cm left adrenal myelolipoma on non-contrast computed tomography of the abdomen performed when she presented for left flank pain due to nephrolithiasis. The biochemical evaluation showed potassium of 2.8 meq/l, plasma aldosterone of 65.9 ng/dl with plasma renin activity of 0.1 ng/ml/hr. An overnight 1 mg dexamethasone suppression test showed nonsuppressible serum cortisol of 10.8 µg/dl. DHEAS, and ACTH were measured at 24.5 µg/dl and <5 pg/ml, respectively. Left adrenalectomy was performed and on the following day, morning serum cortisol was 2.3 µg/dl with aldosterone of 6.2 ng/dl and plasma renin activity of 4.2 ng/ml/hr. Expectedly patient began experiencing nausea, and postural dizziness. Patient systolic blood pressure was in low 100 mmHg. Thus, hydrocortisone therapy was initiated. Immediately postoperatively and thereafter, her blood pressure was controlled with no antihypertensive agent, and morning cortisol measured without hydrocortisone for ~36 h remained low at 1.2 µg/dL. Pathology showed adrenal cortical neoplasm of uncertain malignant potential with associated lipomatous and myelolipomatous metaplasia without atypical mitoses, or lymphovascular invasion, or necrosis, or capsular invasion, with negative surgical margins. Although mitotic activity in the tumor is lacking, the tumor was designated uncertain malignant potential due to the large size (7 cm), and lack of clear cells < 25% according to modified Weiss score.

**Conclusion:** We report a rare case of aldosterone and cortisol co-secreting adrenal cortical neoplasm of uncertain malignant potential with lipomatous and myelolipomatous metaplasia. While the majority of cases of myelolipoma are benign and non-functioning, this case emphasizes the importance of looking for symptoms and signs pointing to adrenal hyperfunction, thorough hormonal and morphologic evaluation and, definitive treatment is curative unilateral adrenalectomy.

*Presentation:* Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m.